期刊文献+

Ki-67和p53在乳腺癌中的表达与临床病理分期的关系 被引量:5

The relationship between the expression of Ki-67 and p53 in breast cancer and its clinical pathological stage
下载PDF
导出
摘要 目的探讨蛋白Ki-67和p53表达与乳腺癌临床病理分期的关系及其对判定预后的价值。方法回顾性分析417例乳腺癌患者病理资料,并对Ki-67和p53的表达情况与临床分期的相关性进行分析。结果本研究共纳入417例乳腺癌患者,蛋白Ki-67阳性385例(92.3%),蛋白p53阳性155例(37.2%),三阴型56例(13.4%),非三阴型361例(86.6%)。蛋白Ki-67和p53的表达与乳腺癌病理组织分型有关(P均<0.05),而与发病时间、淋巴结转移、乳头浸润、TNM分期、病理组织分级、发病年龄、是否绝经、发病部位和直径等因素无关。在三阴性和非三阴性乳腺癌病理组织中,蛋白Ki-67表达差异无统计学意义(P>0.05),p53表达差异有统计学意义(P<0.05)。结论Ki-67和p53在乳腺癌中高表达,对判断预后有一定的价值。 Objective It is to approach the relationships of the expression of protein Ki-67 and P53 in breast cancer with its clinic pathological stage,and predict the value for prognosis. Methods The clinical data of 417 cases of breast cancer were analyzed retrospectively. The relationship of Ki-67 and p53 expression with clinical indexes was analyzed by correlation anal-ysis. Results 417 patients with breast cancer were included. In this study,385 cases(92. 3%)with Ki-67 positive,155 cases(37. 2%)with p53 positive;56 cases(13. 4%)were triple-negative breast cancer,361 cases(86. 6%)were nor-tri-ple negative breast cancer. The expression of Ki-67 and p53 protein was associated with the histopathological classification in breast cancer(all P﹤0. 05),but with no difference in the factors including the time of disease symptom,lymph node metas-tasis,nipple of invasion,TNM stage,histopathologic classification,age,menopausal status,site of cancer and diameter. However,in the groups of triple-negative breast cancer and nor-triple negative,there were obviously difference in expression of p53(P﹤0. 05),but nor in Ki-67(P﹥0. 05). Conclusion High expression of Ki-67 and p53 in breast cancer has certain value in prognosis.
出处 《现代中西医结合杂志》 CAS 2015年第18期1966-1968,共3页 Modern Journal of Integrated Traditional Chinese and Western Medicine
关键词 乳腺肿瘤 病理 蛋白 非组蛋白核蛋白 抑癌基因 breast neoplasms pathology protein Ki - 67 anti-oneogene
  • 相关文献

参考文献6

二级参考文献46

  • 1魏兵,步宏,Anthony Rhodes,张红英.英国国家免疫细胞化学外部质量评估方案及其乳腺病理应用模式[J].中华病理学杂志,2004,33(4):394-395. 被引量:10
  • 2何振宇,李彪,胡英,管迅行.Ki67在乳腺癌组织中的表达及临床病理分析[J].中国初级卫生保健,2005,19(12):94-95. 被引量:16
  • 3Reis-Filho JS,Tutt AN.Triple negative tumours:a critical review[J].Histopathology,2008,52(1):108-118.
  • 4Bauer KR,Brown M,Cress RD,et al.Descriptive analysis of estrogen receptor(ER)-negative,p rogesterone recep tor(PR) -negative,and HER-2-negative invasive breast cancer,the so-called trip le-negative phenotype:a population-based study from the California cancer Registry[J].Cancer,2007,109(9):1721-1 728.
  • 5Cleator S,Heller W,Coombes RC.Triple-negative breast cancer:therapeutic options[J].Lancet Oncol,2007,8 (3):235-244.
  • 6Lund MJ,Butler EN,Bumpers HL,et al.High prevalence of triple-negative tumors in an urban cancer center[J].Cancer,2008,113(3):608-615.
  • 7Sara M,Bando Y,Takahashi M,et al.Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer[J].J Surg Oncol,2008,97(1):30-34.
  • 8Kim MJ,Ro JY,Ahn SH,et al.Clinicopathologic significance of the basal-like subtype of breast cancer:a comparison with hormone receptor and HER-2 /neu-overexpressing phenotypes[J].Hum Pathol,2006,37(9):1217-1226.
  • 9Tischkowitz M,Brunet JS,Begin LR,et al.Use of immunohistochemical markers can refine prognosis in triple negative breast cancer[J].BMC Cancer,2007,7:134.
  • 10Beenken SW,Urist MM,Zhang Y,et al.Axillary lymph node status,but not tumor size,predicts locoregional recurrence and overall survival after mastectomy for breast cancer[J].Ann Surg,2003,237(5):732-738.

共引文献110

同被引文献57

  • 1李娜,胡亚楠,王晓雪,景田园,刘桂霞,杜新磊,王平.鹿角胶化学成分、药理作用及质量控制研究进展[J].中药材,2021,44(7):1777-1783. 被引量:34
  • 2张耀方,梁泽霞,纪金梅,邢焕英,刘汇涛,张丙仓.乳腺癌X线表现特征与P53表达的相关性研究[J].实用放射学杂志,2006,22(10):1264-1266. 被引量:4
  • 3张嫣,郭庆禄,张江宇,叶志球,魏北阳,冯长征,刘永熙.乳腺癌钼靶X线表现与p53表达的相关性探讨[J].广州医药,2007,38(1):54-56. 被引量:6
  • 4Schnitt SJ. Will molecular classification replace traditional breast pathology? [ J ]. Int J Surg Pathol, 2010, 18 ( 3, S ) : 162S-166S.
  • 5Fang Y, Jin RZ, Gao YQ, et al. Design of p53-derived peptides with cytotoxicity on breast cancer [ J ] . Amino Acids, 2014, 46 ( 8 ) : 2015-2024.
  • 6Kuratomi K, Yano H, Tsuneoka M, et al. Immunohistochemical expression of Mina53 and Ki67 proteins in human primary gingival squamous cell carcinoma [ J ] . Kurume Med J, 2006, 53 ( 3-4 ) : 71-78.
  • 7Tanei T, Shimomura A, Shimazu K, et al. Prognostic significance of Ki67 index after neoadjuvant chemotherapy in breast cancer [ J ] . Eur J Surg Oncol, 2011, 37 (2) : 155-161.
  • 8Kim HW, Lee HM, Hwang SH, et al. Patterns and Biologic Features of p53 Mutation Types in Korean Breast Cancer Patients [ J ] . J Breast Cancer, 2014, 17 ( 1 ) : 1-7.
  • 9Kabat GC, Kandel RA, Glass AG, et al. A Cohort Study of p53 Mutations and Protein Accumulation in Benign Breast Tissue and Subsequent Breast Cancer Risk [ J/OL ] . http ://www.hindawi.com/ joumals/jo/2011/970804.
  • 10陈春华,马小敏,丁雅玲.乳腺癌钼靶X线征象与病理学预后因素的相关性研究[J].医药前沿,2014,(21):274-276.

引证文献5

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部